BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Roche (RHHBY) Launches New Thyroid Cancer Monitoring, Diagnosis Test


4/4/2013 8:43:40 AM

April 04, 2013 -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the global launch (except US) of Elecsys Calcitonin, a new laboratory test for the diagnosis and lifelong monitoring of medullary thyroid cancer patients after thyroid surgery.1 Calcitonin is a specific tumour marker that can help healthcare professionals diagnose medullary thyroid carcinoma early, as elevated concentrations of calcitonin in the blood are associated with the onset of this type of cancer. The new test is an important component of medical assessment, especially when the patient’s symptoms are not specific. When performed alongside further examinations, the calcitonin test supports final clinical clearance. Patients can be treated at an earlier stage with greater chances of success.2

Designed for use on Roche’s cobas modular analyser platform, Elecsys Calcitonin offers healthcare professionals an integrated solution for accurate diagnosis and reliable patient monitoring, significantly improving medical decision-making and treatment planning.

“The development of new laboratory tests for cancer management reflects our key goal of diagnostic solutions that support healthcare professionals with clear, actionable information and can thus contribute to increasing patient survival,” said Roland Diggelmann, Chief Operating Officer, Roche Diagnostics.

The thyroid is a butterfly-shaped gland located at the front of the throat. One of the largest endocrine glands, it produces hormones which control the body’s metabolism. Medullary thyroid carcinoma is the third most common type of thyroid cancer, accounting for 5–10% of all thyroid cancers. Treatment usually involves extensive surgical removal of the thyroid gland, followed by lifelong relapse monitoring, usually every six months.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References:

1) Cooper, D.S. et al. (2009). Thyroid 19, 1167-1214.

2) Elisei, R. et al. (2012), A. Nat. Rev. Endocrinol. 8, 466–475 (2012); published online 3 April 2012.



Read at BioSpace.com

Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES